{"ok":true,"trend":{"id":415637,"platform":"google","region":"US","key":"retatrutide","title":"retatrutide","url":"https://trends.google.com/trending?geo=US&q=retatrutide","first_seen":"2026-09-29T23:35:48.135970Z","last_seen":"2026-09-29T23:50:48.233054Z","last_rank":10,"peak_rank":5,"last_volume":1000,"peak_volume":1000,"seen_count":2,"score":0.513125,"category_hint":null,"section":null,"category":null,"summary":"Retatrutide, an experimental obesity drug from Eli Lilly, is drawing attention after trial results showed participants losing up to 25% of their body weight, making it potentially the most powerful obesity drug tested to date. Coverage, including Ars Technica's report on the findings, is fueling discussion about how it might compare to established treatments like tirzepatide and semaglutide.","why":"New trial results suggest retatrutide could outperform current obesity medications, prompting widespread interest.","tone":"positive","entities":["Retatrutide","Eli Lilly","Ars Technica"],"summarized_at":"2026-09-29T23:38:29.840411Z","meta":{"lang":"en","picture":"https://encrypted-tbn3.gstatic.com/images?q=tbn:ANd9GcSrPNt_8_Ac-mU3zIiRrTBIRfP5JflYy-tupix7R3c-d22jrIbztMRWc9eLD-Q","traffic":"1000+","published":"Tue, 29 Sep 2026 16:20:00 -0700","picture_source":"The Guardian"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Retatrutide shows up to 25% weight loss in trial","timeline":[{"captured_at":"2026-09-29T23:35:48.135970Z","rank":5,"volume":1000},{"captured_at":"2026-09-29T23:50:48.233054Z","rank":10,"volume":1000}],"posts":[{"platform":"google","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-experimental-drug-cuts-weight-by-21-diabetes-trial-2026-09-29/","author":"Reuters","title":"Lilly's experimental drug cuts weight by 21% in diabetes trial","snippet":null,"posted_at":null,"likes":null},{"platform":"google","url":"https://arstechnica.com/health/2026/09/most-powerful-obesity-drug-yet-people-lost-up-to-25-of-weight-in-trial/","author":"Ars Technica","title":"Most powerful obesity drug yet: People lost up to 25% of weight in trial","snippet":null,"posted_at":null,"likes":null}],"elsewhere":[{"id":416929,"platform":"google","region":"GB","title":"retatrutide","last_rank":10,"last_seen":"2026-09-30T04:35:46.961762Z","summary":"Eli Lilly's experimental drug retatrutide is drawing global attention after new trial results showed people lost up to 25% of their body weight, with patients who have Type 2 diabetes shedding as much as 60 pounds, or roughly 21% of their weight. Outlets including Reuters, NBC News and Ars Technica describe it as potentially the most powerful obesity drug yet, and searches are spiking in the US, UK and Brazil."},{"id":419585,"platform":"google","region":"BR","title":"retatrutide","last_rank":7,"last_seen":"2026-09-30T02:05:47.190219Z","summary":"Retatrutide, an experimental obesity drug from Eli Lilly, is drawing major attention after trial results showed participants losing up to 25% of their body weight, reportedly making it the most powerful obesity drug tested so far. The findings are fueling discussion about the next generation of weight-loss treatments beyond semaglutide and tirzepatide, with strong interest in the US, UK and Brazil."}],"window":"7d"}}